Caris Life Sciences Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Caris Life Sciences Inc (CAI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Caris Life Sciences Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 990M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+6.6% annualized vs trailing 12 months).
- Scale: Caris Life Sciences Inc ranks #6 of 26 companies by market capitalization in the Rental & Leasing industry, holding 5.3% of industry market cap.
- Peer revenue share: Caris Life Sciences Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CAI Sales vs. its Competitors, Q2 2026
Caris Life Sciences Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Rental & Leasing industry grew revenue 10.5% year over year, combined, vs 45.4% for Caris Life Sciences Inc. Caris Life Sciences Inc's share of combined industry revenue moved from 0.56% to 0.74%, a gain of 0.18 percentage points.
Caris Life Sciences Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Caris Life Sciences Inc | Yes | Yes | Yes | No |
| High-Confidence Competitors (13) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 50.00 % (4 of 8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CAI Stock Performance relative to its Competitors
CAI Stock Performance relative to High-Confidence Competitors
CAI Stock Performance relative to Similar-Size Competitors
CAI Stock Performance relative to Similar Growth & Profitability Competitors
Caris Life Sciences Inc's Comment on Competition and Industry Peers
Caris Life Sciences Inc's Competitors Named by the Company
Competitive relationships identified from Caris Life Sciences Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Personalis | Company report | 85% |
| Natera | Company report | 85% |
| Guardant Health | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Adaptive Biotechnologies | Company report | 85% |
| Freenome | Company report | 85% |
| Tempus | Company report | 85% |
| Exact Sciences | Company report | 85% |
| Illumina | Company report | 85% |
| Quest Diagnostics | Company report | 85% |
| Zenta Group Company Limited | Company report | 85% |
| BillionToOne | Company report | 85% |
| Grail | Company report | 85% |
| New York Presbyterian—Weil Cornell | Company report | 85% |
| Sophia Genetics Sa | Company report | 85% |
| Foundation Medicine (Roche) | Company report | 85% |
| Memorial Sloan Kettering Cancer Center | Company report | 85% |
| SAGA Diagnostics | Company report | 85% |
| Delfi Diagnostics | Company report | 85% |
Company report basis, confidence, active dates and source counts for Caris Life Sciences Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Caris Life Sciences Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.